Carbohydrate antigen 19–9 is significantly elevated in autosomal dominant polycystic kidney disease

Aim Liver cysts are the most common extrarenal manifestation in patients with autosomal dominant polycystic kidney disease (ADPKD). Carbohydrate antigen 19–9 (CA19–9) is generally used as a marker for biliopancreatic malignancies, although CA19–9 levels in patients with ADPKD are largely unknown. Me...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology (Carlton, Vic.) Vic.), 2018-03, Vol.23 (3), p.210-216
Main Authors: Fukasawa, Hirotaka, Kaneko, Mai, Niwa, Hiroki, Yasuda, Hideo, Kumagai, Hiromichi, Furuya, Ryuichi
Format: Article
Language:English
Subjects:
Antigens
autosomal dominant polycystic kidney disease (ADPKD)
Blood pressure
carbohydrate antigen 19–9 (CA19–9)
cyst volume
Cysts
Differential diagnosis
gamma‐glutamyl transferase (GTP)
Guanosine triphosphate
Kidney diseases
Kidneys
Liver
liver cysts
Liver diseases
Polycystic kidney
Serum levels
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Liver cysts are the most common extrarenal manifestation in patients with autosomal dominant polycystic kidney disease (ADPKD). Carbohydrate antigen 19–9 (CA19–9) is generally used as a marker for biliopancreatic malignancies, although CA19–9 levels in patients with ADPKD are largely unknown. Methods A prospective observational study of 53 ADPKD patients and 83 non‐ADPKD control subjects was performed. The serum levels of CA19–9 were studied to evaluate the association with clinical parameters and liver cysts. Results The serum CA19–9 levels were significantly higher in the ADPKD group than in the control group (32.9 U/mL vs. 9.8 U/mL, respectively, P 
ISSN:1320-5358
1440-1797
DOI:10.1111/nep.12988